secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001104659-25-041862
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus announces $22M private placement, Q1 revenue up 42% to $9.2M
---------------------------------------------------------------------

- Private placement of 5.5M shares at $4.00/share raises ~$22M gross; led by Nantahala Capital, Broadfin Holdings. Expected close May 2, 2025.
- Preliminary Q1 2025 revenue ~$9.2M (solely from TriNav Infusion System), +42% YoY.
- Exchange offer for Series A Preferred Stock: each share exchanged for common at formula based on $10.00 liquidation preference plus accrued dividends through Aug 2027 divided by $4.00.
- Special meeting to vote on amendment allowing company to call Preferred Stock for conversion and eliminate July 2027 conversion price reset.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465925041862/0001104659-25-041862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465925041862/tm2513482d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-041862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer